Inotek initiates phase 2 trial for fixed-dose combination of trabodenoson, latanoprost

Inotek Pharmaceuticals has initiated a phase 2 dose-ranging trial of a fixed-dose combination of trabodenoson and latanoprost for the treatment of patients with ocular hypertension or primary open-angle glaucoma, the company announced in a press release.The randomized, double-masked trial will include approximately 165 patients with an IOP between 25 mm Hg and 34 mm Hg. Patients will receive various topical combinations of trabodenoson and latanoprost or latanoprost alone over 8 weeks.